The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
India saline solution market reached a value of US$ 518 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 925 Million by 2027, exhibiting at a CAGR of 10.0% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor.
Saline solutions refer to supplement fluids comprising of water, electrolytes, and sugar. These solutions are given to patients according to their medical requirements, age, and body size to restore fluid volume and maintain electrolyte balance. Some of the common product types include normal saline, Ringer’s lactate solution, dextrose, etc. Saline solutions are either applied topically or used intravenously to administer drugs and essential food nutrients in the body when a patient is unable to consume the same orally. Saline solutions are widely adopted across hospitals, clinics, ambulatory surgical centers, home care centers, etc.
The high prevalence of numerous chronic diseases, including cardiovascular diseases (CVDs), neurological disorders, cancer, etc., that usually require surgeries and hospitalization, is primarily driving the demand for saline solutions in India. In line with this, the growing occurrences of hyponatremia (sodium deficiency), particularly among the geriatric population, are further augmenting the need for saline solutions. Additionally, the continuous upgradation of medical facilities, along with increasing consumer consciousness towards early disease detection and their effective treatment, is also propelling the market growth in the country. Moreover, the rising participation of individuals in physical activities is catalyzing the adoption of saline solutions for treating chronic dehydration that can cause fatigue, appetite loss, irritability, etc. Apart from this, several product manufacturers are introducing easy-to-use, portable packaging materials for saline solutions that can be used as drips in homecare settings. Furthermore, the Indian government is also focusing to enhance the domestic production of saline solutions under the ‘Make in India’ initiative, which is acting as another significant growth-inducing factor. With the sudden outbreak of the COVID-19 pandemic, there is a rise in demand for saline solutions to provide essential nutrients to patients admitted to the intensive care unit (ICU). All of these above-mentioned factors are expected to drive the India saline solution market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the India saline solution market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on product type, packaging type, end-use and application.
Breakup by Product Type:
Breakup by Packaging Type:
Breakup by End-Use:
Breakup by Application:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abaris Healthcare, Aculife Healthcare Pvt. Ltd. (Nirma Chemical Works Pvt Ltd.), Albert David limited, Althea Pharma, Amanta Healthcare, B Braun India Pvt. Ltd., Eurolife Healthcare Pvt. Ltd., Fresenius Kabi India Pvt. Ltd. (Fresenius Kabi AG) and Otsuka Pharmaceutical Co. Ltd. (Otsuka Holdings Co.,Ltd).
|Base Year of the Analysis||2021|
|Units||US$ Million, Million Bottles|
|Segment Coverage||Product Type, Packaging Type, End-Use, Application, Region|
|Region Covered||South India, North India, West and Central India, East India|
|Companies Covered||Abaris Healthcare, Aculife Healthcare Pvt. Ltd. (Nirma Chemical Works Pvt Ltd.), Albert David limited, Althea Pharma, Amanta Healthcare, B Braun India Pvt. Ltd., Eurolife Healthcare Pvt. Ltd., Fresenius Kabi India Pvt. Ltd. (Fresenius Kabi AG) and Otsuka Pharmaceutical Co. Ltd. (Otsuka Holdings Co.,Ltd).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at